ESPERITE (ESP) resumes negotiations regarding proposed sale of stem cell banking business to PBKM.

Alleen voor leden beschikbaar, wordt daarom gratis lid!

Algemeen advies 13/06/2019 07:20
Esperite N.V. (Euronext: ESP, “Esperite”) announces today that it has resumed negotiations with Polski Bank Komórek Macierzystych S.A. (WSE: PBKM, “PBKM”) regarding the proposed sale of certain assets and liabilities related to Cryo-Save’s stem cell banking business (the Proposed Sale). The negotiations were resumed by Esperite after receiving an expression of renewed interest by PBKM, as announced today by PBKM. As of today, the parties have not yet reached agreement on the terms of the Proposed Sale.
As disclosed previously, the MoU regarding the Proposed Sale, including the exclusivity granted to PBKM, was terminated on 28 May 2019.
About ESPERITE
ESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000.

tijd 10.02
Esperite EUR 0,0948 +2,36ct vol. 2,3 milj.



Beperkte weergave !
Leden hebben toegang tot meer informatie! Omdat u nog geen lid bent of niet staat ingelogd, ziet u nu een beperktere pagina. Wordt daarom GRATIS Lid of login met uw wachtwoord


Copyrights © 2000 by XEA.nl all rights reserved
Niets mag zonder toestemming van de redactie worden gekopieerd, linken naar deze pagina is wel toegestaan.


Copyrights © DEBELEGGERSADVISEUR.NL